Summit Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 1
- Connections
- 30
What's happening
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
Summit Therapeutics is undergoing FDA review for a drug.Some support2 reports
-
Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.Speculative1 report4 developments inside
-
Institutional investors bought and sold stock in Summit Therapeutics.Some support1 report
-
Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.Some support1 report
-
Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.Some support3 reports1 development inside
-
Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.Some support5 reports
-
Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Summit Therapeutics this week
News at the entities that move Summit Therapeutics most-
FDA StructuralThe FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.Moves Summit Therapeutics
-
AstraZeneca OperationalAstraZeneca developed the drug Ultomiris, supported by the UAE's Emirates Drug Establishment (EDE).Moves Summit Therapeutics
-
Europe StructuralFalaise, a town, is highlighted for its connection to invasions that shaped Europe's history.Moves Summit Therapeutics
-
Cantor Fitzgerald Mentioned togetherCantor Fitzgerald, Citigroup, and MarketBeat issued rating updates and price targets for Rigel Pharmaceuticals, Inc.Moves Summit Therapeutics
-
MarketBeat Mentioned togetherMarketBeat provided average stock rating data for SS Innovations International, Inc. on June 6, 2026.Moves Summit Therapeutics
-
Barclays Mentioned togetherBarclays changed Arkema's stock rating on November 10, 2026.Moves Summit Therapeutics
Connections
The 12 strongest of 30, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Akeso Structural
Summit Therapeutics relies on Akeso's core IP and engineering expertise for the co-development and commercialization of ivonescimab.
-
FDA Structural
Summit Therapeutics is currently undergoing review by the FDA, which sets the standards for drug approval and market access.
-
AstraZeneca Operational
Summit Therapeutics and AstraZeneca maintain a strategic collaboration focused on developing oncology treatments and expanding drug reach.
-
Revolution Medicines (United States) Operational
The companies are engaged in a clinical collaboration to evaluate drug combinations for cancer treatment.
-
Merck Operational
Summit Therapeutics and Merck are direct competitors in the pharmaceutical market, with A's drug ivonescimab being clinically pitted against Merck's Keytruda.
-
Europe Structural
Summit Therapeutics holds proprietary rights and markets drugs within the European territory.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald analysts have provided positive ratings and commentary on Summit Therapeutics' drug data.
-
Elon Musk Mentioned together
The evidence places both entities in the category of high-earning tech executives.
Show all 12 connections
-
Leerink partners Mentioned together
Leerink Partners provided a stock rating upgrade for Summit Therapeutics.
-
MarketBeat Mentioned together
MarketBeat provides stock average ratings for Summit Therapeutics.
-
MIaMI Shared context
Summit Therapeutics is headquartered in Miami.
-
Barclays Mentioned together
Barclays provides financial analysis, specifically raising a price objective, for Summit Therapeutics.
History
Events by the month they beganNovember 2026
1 eventSeptember 2026
1 eventJuly 2026
2 eventsShow 1 earlier month
June 2026
6 events- Summit Therapeutics and AstraZeneca announced a partnership on July 4, 2025, to collaborate on lung cancer drug development.
- Chinese biopharma is gaining ground, producing oncology drugs that rival established Western pharmaceuticals like those associated with Merck.
- Vertex Pharmaceuticals, Eli Lilly, and Summit Therapeutics are drugmakers with ongoing clinical trials.
- Revolution Medicines and Summit Therapeutics announced a collaboration on August 19, 2025, to evaluate combination therapies.
- Summit Therapeutics acquired an exclusive license from Akeso for developing bispecific assets, with ivonescimab showing strong results compared to Keytruda.
- Revolution Medicines and Summit Therapeutics are collaborating to evaluate combination therapies using RAS inhibitors and ivonescimab for targeted cancer treatment.